1 month Eli Lilly and Novo Nordisk’s Obesity Moat Just Got Stronger The Wall Street Journal
Data from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.
Amgen (AMGN) · Biotech · Eli Lilly (LLY)
XData from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.
Amgen (AMGN) · Biotech · Eli Lilly (LLY)
X